Condition: Aortic Valve Stenosis · Heart Failure · Sponsor: Duk-Woo Park, MD
The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.
This description comes directly from the study's public registry record.
Jeong-youn Bae, Project manager · 82230107259 · cvcrc10@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Bucheon Sejong Hospital | Bucheon-si, South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon, South Korea | Recruiting |
| Daegu Catholic University Medical Center | Daegu, South Korea | Recruiting |
| Keimyung University Dongsan Medical Center | Daegu, South Korea | Recruiting |
| Kyungpook National University Hospital | Daegu, South Korea | Recruiting |
| Yeungnam University Medical Center | Daegu, South Korea | Withdrawn |
| Chungnam National University Hospital | Daejeon, South Korea | Recruiting |
| The Catholic University of Korea, Daejeon ST. Mary's Hospital | Daejeon, South Korea | Recruiting |
| Gangneung Asan Hospital | Gangneung, South Korea | Recruiting |
| Chonnam National University Hospital | Gwangju, South Korea | Recruiting |
| Inje University Ilsan Paik Hospital | Ilsan, South Korea | Recruiting |
| Gachon University Gil Hospital | Incheon, South Korea | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05672836